733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins

od Borroto-Esoda, Katyna, Angulo, David A, Azie, Nkechi
izdano v Open Forum Infect Dis (2020)

The Prospective Antifungal Therapy Alliance(®) registry: A two-centre Canadian experience

od Haider, Shariq, Rotstein, Coleman, Horn, David, Laverdiere, Michel, Azie, Nkechi
Izdano 2014

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model

od Borroto-Esoda, Katyna, Azie, Nkechi, Ashbaugh, Alan, Cushion, Melanie, Angulo, David A
izdano v Open Forum Infect Dis (2020)

Intravenous diltiazem and CYP3A-mediated metabolism

od Masica, Andrew L, Azie, Nkechi E, Brater, D Craig, Hall, Stephen D, Jones, David R
Izdano 2000

Safety and Pharmacokinetic Profiles of Repeated-Dose Micafungin in Children and Adolescents Treated for Invasive Candidiasis

od Benjamin, Daniel K., Deville, Jaime G., Azie, Nkechi, Kovanda, Laura, Roy, Mike, Wu, Chunzhang, Arrieta, Antonio
Izdano 2013

Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, o...

od Marukutira, Tafireyi, Huprikar, Shirish, Azie, Nkechi, Quan, Shun-Ping, Meier-Kriesche, Herwig-Ulf, Horn, David L
Izdano 2014

202 Antifungal Stewardship: The Clinician's Perspective on Barriers to Implementation

od Safdar, Amar, Goff, Debra, Gallagher, Jason, Hsu, Donald, Eiland, Edward, Hanrahan, Jennifer, Smith, Purvi, Azie, Nkechi
izdano v Open Forum Infect Dis (2014)

Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis

od Gebremariam, Teclegiorgis, Wiederhold, Nathan P., Alqarihi, Abdullah, Uppuluri, Priya, Azie, Nkechi, Edwards, John E., Ibrahim, Ashraf S.
izdano v J Antimicrob Chemother (2017)

Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents

od Hope, William W., Kaibara, Atsunori, Roy, Michael, Arrieta, Antonio, Azie, Nkechi, Kovanda, Laura L., Benjamin, Daniel K.
izdano v Antimicrob Agents Chemother (2015)

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis

od Harrington, Rachel, Lee, Edward, Yang, Hongbo, Wei, Jin, Messali, Andrew, Azie, Nkechi, Wu, Eric Q., Spalding, James
izdano v Adv Ther (2016)

A Risk Score for Fluconazole Failure among Patients with Candidemia

od Ostrosky-Zeichner, Luis, Harrington, Rachel, Azie, Nkechi, Yang, Hongbo, Li, Nanxin, Zhao, Jing, Koo, Valerie, Wu, Eric Q.
izdano v Antimicrob Agents Chemother (2017)

Comparing Methods of Measurement for Detecting Drug‐Induced Changes in the QT Interval: Implications for Thoroughly Conducted ECG Studies

od Azie, Nkechi E., Adams, Gregory, Darpo, Borje, Francom, Steven F., Polasek, Emery C., Wisser, Joy M., Fleishaker, Joseph C.
izdano v Ann Noninvasive Electrocardiol (2004)

Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans

od Fleishaker, Joseph C, Ryan, Kristi K, Jansat, Josep M, Carel, Barabara J, Bell, David J A, Burke, Moira T, Azie, Nkechi E
Izdano 2001

Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008

od Pfaller, Michael A., Andes, David R., Diekema, Daniel J., Horn, David L., Reboli, Annette C., Rotstein, Coleman, Franks, Billy, Azie, Nkechi E.
Izdano 2014

Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study

od Kontoyiannis, Dimitrios P., Yang, Hongbo, Song, Jinlin, Kelkar, Sneha S., Yang, Xi, Azie, Nkechi, Harrington, Rachel, Fan, Alan, Lee, Edward, Spalding, James R.
izdano v BMC Infect Dis (2016)

Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients

od Andes, David, Azie, Nkechi, Yang, Hongbo, Harrington, Rachel, Kelley, Caroline, Tan, Ruo-Ding, Wu, Eric Q., Franks, Billy, Kristy, Rita, Lee, Edward, Khandelwal, Nikhil, Spalding, James
izdano v Antimicrob Agents Chemother (2016)

Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental In...

od Petraitis, Vidmantas, Petraitiene, Ruta, Katragkou, Aspasia, Maung, Bo Bo Win, Naing, Ethan, Kavaliauskas, Povilas, Barat, Stephen, Borroto-Esoda, Katyna, Azie, Nkechi, Angulo, David, Walsh, Thomas J.
izdano v Antimicrob Agents Chemother (2020)

Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections

od Ghannoum, Mahmoud, Arendrup, Maiken Cavling, Chaturvedi, Vishnu P., Lockhart, Shawn R., McCormick, Thomas S., Chaturvedi, Sudha, Berkow, Elizabeth L., Juneja, Deven, Tarai, Bansidhar, Azie, Nkechi, Angulo, David, Walsh, Thomas J.
izdano v Antibiotics (Basel) (2020)

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses

od Thompson, George R., Rendon, Adrian, Ribeiro dos Santos, Rodrigo, Queiroz-Telles, Flavio, Ostrosky-Zeichner, Luis, Azie, Nkechi, Maher, Rochelle, Lee, Misun, Kovanda, Laura, Engelhardt, Marc, Vazquez, Jose A., Cornely, Oliver A., Perfect, John R.
izdano v Clin Infect Dis (2016)

1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)

od Alexander, Barbara D, Cornely, Oliver, Pappas, Peter, Miller, Rachel, Vazquez, Jose A, Ostrosky-Zeichner, Luis, Spec, Andrej, Rautemaa-Richardson, Riina, Krause, Robert, Thompson III, George R, Morse, Caryn, Sanders, John W, Andes, David, Andes, David, Lyon, George, Marty, Francisco M, Silverman, Emily, Miceli, Marisa H, Patterson, Thomas F, Hoenigl, Martin, Azie, Nkechi, Angulo, David A
izdano v Open Forum Infect Dis (2020)